Schwab Charles Investment Management Inc. lifted its stake in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 5.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 322,424 shares of the biotechnology company’s stock after purchasing an additional 15,581 shares during the period. Schwab Charles Investment Management Inc. owned about 0.46% of Progenics Pharmaceuticals worth $2,374,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in PGNX. Legal & General Group Plc boosted its holdings in Progenics Pharmaceuticals by 9.4% in the second quarter. Legal & General Group Plc now owns 127,423 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 10,947 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Progenics Pharmaceuticals by 58.7% in the second quarter. BNP Paribas Arbitrage SA now owns 20,565 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 7,604 shares during the period. Principal Financial Group Inc. boosted its holdings in Progenics Pharmaceuticals by 8.7% in the second quarter. Principal Financial Group Inc. now owns 594,849 shares of the biotechnology company’s stock valued at $4,039,000 after purchasing an additional 47,647 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Progenics Pharmaceuticals during the 2nd quarter worth about $108,000. Finally, Teachers Advisors LLC lifted its holdings in Progenics Pharmaceuticals by 70.6% during the 2nd quarter. Teachers Advisors LLC now owns 205,501 shares of the biotechnology company’s stock worth $1,395,000 after buying an additional 85,022 shares during the last quarter. Hedge funds and other institutional investors own 84.55% of the company’s stock.

Shares of Progenics Pharmaceuticals, Inc. (PGNX) opened at $6.22 on Thursday. The stock has a market capitalization of $437.08, a PE ratio of -7.87 and a beta of 3.42. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.80. Progenics Pharmaceuticals, Inc. has a fifty-two week low of $4.60 and a fifty-two week high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. The business had revenue of $2.70 million during the quarter, compared to the consensus estimate of $3.58 million. During the same period in the previous year, the business earned $0.52 EPS. The business’s quarterly revenue was down 95.0% on a year-over-year basis. sell-side analysts predict that Progenics Pharmaceuticals, Inc. will post -0.92 earnings per share for the current fiscal year.

A number of analysts have issued reports on PGNX shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 price target on shares of Progenics Pharmaceuticals in a report on Thursday, November 2nd. Zacks Investment Research raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a report on Thursday, January 4th. BidaskClub raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 9th. Finally, ValuEngine raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $12.35.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2018/01/18/schwab-charles-investment-management-inc-buys-15581-shares-of-progenics-pharmaceuticals-inc-pgnx.html.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.